100% reduction of target lesions in one melanoma and one pancreatic cancer patient observed among 4 Partial Responses (PR) to date which include 2 of 4 evaluable dose expansion patients and 2 of 2 MSI-H patients

See the original post here:
Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2...

- Pre-clinical results demonstrate the combination of FMC-376 with PD-1 immunotherapy increases survival and response rates compared to PD-1 alone

Link:
Frontier Medicines Presents New Data for First-In-Class Dual ON+OFF KRAS G12C Inhibitor FMC-376 at the AACR Annual Meeting

- Preclinical data supports potential for proprietary nsCAR platform to selectively eliminate cancer cells while preserving healthy tissue

See original here:
IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024

First-in class BRM (SMARCA2) selective inhibitor FHD-909 demonstrated favorable tolerability and dose-dependent single agent activity in BRG1 mutated cancers preclinically; IND filing on track for Q2 2024

Link:
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300...

Preclinical data from lead program addressing AURIGIN-identified KAT2A/B target showed significant cell state shift and tumor growth inhibition across multiple primary cancer models

Read more:
Auron Unveils Preclinical Data Supporting its Lead Program and Ability of its AURIGIN™ Platform to Generate Targeted Cancer Therapies at AACR Annual...

Highly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at well-tolerated doses

View original post here:
Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting

FOSTER CITY, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable” or the “Company”), a clinical-stage precision oncology company developing a new class of cancer therapies identified by its Predictive Precision Medicine Platform (PPMP), today presented the design for the PPMP-enabled Phase 2 trial with volasertib, in combination with decitabine, in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) at the American Association for Cancer Research (AACR 2024) being held in San Diego, CA (Poster abstract 5178).

See the original post here:
Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024

– Twenty patients with indolent (n=18) and aggressive (n=2) R/R B-NHL received evorpacept plus standard rituximab and lenalidomide (“R2”)– Evorpacept plus R2 was well tolerated with a safety profile similar to historical R2– The combination achieved promising initial activity with a best overall response rate (“ORR”) of 94% and a complete response rate (“CRR”) of 83% in patients with indolent R/R B-NHL (R2 historical CRR benchmark is 34%)

Original post:
ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients...

SYDNEY, Australia, April 09, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (the Company), the Company developing a new class of synthetic anti-infectives, today announced its selection by the United Kingdom’s (UK) Government Innovation Agency (Innovate UK) to partake in the prestigious UK Antimicrobial Resistance (AMR) Inward Mission 2024. This event, set to take place from June 2-7, 2024, will spotlight the Company as one of the promising organizations from across the globe recognized for its potential to combat AMR.

Visit link:
Recce Pharmaceuticals Selected by UK Government Innovation Agency to Participate in AMR Mission 2024

Philadelphia Wings player, Connecticut man will be forever bonded by bone marrow donation: "He's my hero"  CBS Philly

Read the original here:
Philadelphia Wings player, Connecticut man will be forever bonded by bone marrow donation: "He's my hero" - CBS Philly

VRD versus VCD as induction therapy before autologous stem cell transplantation in multiple myeloma: a nationwide ...  Nature.com

The rest is here:
VRD versus VCD as induction therapy before autologous stem cell transplantation in multiple myeloma: a nationwide ... - Nature.com

Register as a bone marrow donor today and save lives  The Citizen

View post:
Register as a bone marrow donor today and save lives - The Citizen

Data demonstrate compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through Ampligen Data demonstrate compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through Ampligen

View original post here:
AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal...

AUSTIN, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced the completion of another interim safety review of simufilam in on-going Phase 3 clinical trials in patients with Alzheimer’s disease. A routine, scheduled meeting of a Data and Safety Monitoring Board (DSMB) recommended that both of Cassava Sciences’ on-going Phase 3 studies continue as planned, without modification.

Go here to see the original:
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials

THE WOODLANDS, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that four data presentations related to sotagliflozin, an inhibitor of two sodium glucose transport proteins (SGLT2 and SGLT1), will be delivered during the American College of Cardiology 73rd Annual Scientific Session & Expo being held April 6 - 8, 2024 in Atlanta, Georgia, including results from a post-hoc evaluation of the efficacy of sotagliflozin in reducing stroke events in patients with type 2 diabetes, chronic kidney disease (CKD), and high cardiovascular (CV) risk in the SCORED Phase 3 clinical trial.

See the original post here:
Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of...

Specialty Pharmaceutical Company Deploys TransPerfect Technology to Streamline TMF Operations Specialty Pharmaceutical Company Deploys TransPerfect Technology to Streamline TMF Operations

See the article here:
Gedeon Richter Selects Trial Interactive for Clinical Trial Management

Revisionen af selskabets årsrapport for 2023 er ikke afsluttet. Årsrapporten offentliggøres på onsdag den 27. marts 2024 i henhold til selskabets finanskalender.

Read this article:
Foreløbige tal for 2023 og finansielle forventninger til 2024

OXURION announces its presence at the Paris SmallCapevent on March 28, 2024.

More here:
OXURION announces its presence at the Paris SmallCap event on March 28, 2024.

Topline data from the randomized Phase 2b KICKSTART trial of tomivosertib combined with pembrolizumab in non-small cell lung cancer (NSCLC) expected in early April 2024

Read the original:
eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

RESEARCH TRIANGLE PARK, N.C., March 25, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 28, 2024, at 2:30 p.m. ET and the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 10:15 a.m. ET.

Read more:
BioCryst to Present at Upcoming Investor Conferences